An experience of therapy with nintedanib in patients with idiopathic pulmonary fibrosis

Abstract

Idiopathic pulmonary fibrosis (IPF) is the most common clinical variant of idiopathic interstitial pneumonia. Pathophysiology of IPF involves recurrent damage of the alveolar epithelium with fibroblast excessive proliferation as aberrant reparative activity of the lung interstitium. Currently, a treatment approach to this disease has been revised. Given new knowledge on pathogenesis of IPF, an international evidencebased clinical guideline published in 2015 recommends antifibrotic agents as the basic therapy of IPF. The only antifibrotic agent registered in Russia is niintedanib. A clinical case of IPF with the first experience of therapy with nintedanib in Omsk region has been reported in the article.